<DOC>
	<DOCNO>NCT02311907</DOCNO>
	<brief_summary>This randomized phase III trial study glutathione see well work prevent peripheral neuropathy cause paclitaxel carboplatin patient ovarian cancer , fallopian tube cancer , and/or primary peritoneal cancer . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Chemoprotective drug , glutathione , may help prevent peripheral neuropathy cause paclitaxel carboplatin . It yet know whether glutathione effective placebo prevent peripheral neuropathy .</brief_summary>
	<brief_title>Glutathione Preventing Peripheral Neuropathy Caused Paclitaxel Carboplatin Patients With Ovarian Cancer , Fallopian Tube Cancer , and/or Primary Peritoneal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare TAXOL ( paclitaxel ) /carboplatin ( CBDCA ) induce peripheral neuropathy measure European Organization Research Treatment Cancer ( EORTC ) - Quality Life ( QOL ) -chemotherapy induced peripheral neuropathy 20 ( CIPN20 ) glutathione ( GSH ) placebo arm . SECONDARY OBJECTIVES : I . To compare incidence grade 2+ grade 3+ TAXOL/CBDCA induce peripheral neuropathy measure Common Terminology Criteria Adverse Events ( CTCAE ) neuropathy scale GSH placebo arm . II . To compare time onset grade 2+ grade 3+ TAXOL/CBDCA induce peripheral neuropathy GSH placebo arm , measure CTCAE neuropathy scale . III . To compare proportion patient require chemotherapy dose reduction secondary TAXOL/CBDCA induce peripheral neuropathy GSH placebo arm . IV . To compare proportion patient stop TAXOL/CBDCA secondary peripheral neuropathy GSH placebo arm . V. To assess toxicity profile GSH situation . VI . To evaluate whether GSH influence anti-tumor activity TAXOL/CBDCA . VII . To evaluate patient quality life ( QOL ) measure Functional Assessment Cancer Therapy-Ovarian ( FACT-O ) ( ovarian/fallopian tube/primary peritoneal cancer patient ) patient daily symptom questionnaire time GSH placebo arm . TERTIARY : I . To explore association genetic variation gene involve taxane/platinum metabolism incidence grade 2+ TAXOL/CBDCA induce peripheral neuropathy . II . As part ongoing research North Central Cancer Treatment Group ( NCCTG ) study , bank blood product future study . OUTLINE : Patients stratify accord baseline neuropathy ( none v grade 1 ) , debulked status ( gross residual disease [ clinically apparent residual lesion completion primary surgery ] v optimal [ large residual lesion &lt; 1 cm primary surgery ] v sub-optimally debulked [ residual lesion &gt; 1 cm ] operate upon ) , cancer type ( ovarian/fallopian tube/primary peritoneal cancer vs lung cancer v ) . Patients randomize 1 2 treatment arm . Patients group base , Planned paclitaxel dose cycle length ( Weekly vs. every 3 week vs. every 4 week ) . The stratification factor list include demographic , prognostic factor medication potentially impact primary secondary outcome , need distribute evenly among two arm . The 18 level combination involve four stratification factor within maximum recommend one half group sample size study . Ideally , patient begin receive glutathione first dose chemotherapy , must begin glutathione second dose chemotherapy . ARM I : Patients receive glutathione intravenously ( IV ) 15 minute , paclitaxel* IV 1 3 hour depend plan dose cycle length carboplatin IV 30 minute . ARM II : Patients receive placebo IV 15 minute , paclitaxel* IV 1 3 hour depend plan dose cycle length carboplatin IV 30 minute . NOTE : *Alternatively , patient may receive paclitaxel IV 1 hour glutathione/placebo IV 15 minute weekly carboplatin every 21 day 12 week . Blood sample collect periodically pharmacogenomic biomarker analysis . Patients complete questionnaire periodically , include quality-of-life assessment . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Scheduled undergo treatment TAXOL 150200 mg/m2 CBDCA area curve ( AUC ) = 57 every 21 28 day least 12 week ; alternatively , paclitaxel prescribe 80 mg/m2 weekly least 12 week , CBDCA dose AUC = 57 every 21 day ; additional chemotherapy agent allow ( bevacizumab , etoposide , etc ) per physician discretion , long know neurotoxic ; Note : patient ideally begin GSH therapy prior first dose chemotherapy , must begin GSH therapy prior second dose chemotherapy Ability sign inform consent understand nature placebocontrolled trial Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Ability complete English language questionnaire ( ) assistance Life expectancy &gt; = 6 month Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential , per clinician discretion Willingness provide blood specimen require protocol White blood cell ( WBC ) &gt; = 3400 Absolute neutrophil count ( ANC ) &gt; = 1500 Platelet ( PLT ) &gt; = 100,000 Hemoglobin ( HgB ) &gt; 10.0 Creatinine = &lt; 1.5 x upper limit normal ( ULN ) Preexisting history peripheral neuropathy &gt; grade 1 ( National Cancer Institute [ NCI ] CTCAE version [ v ] 4.0 ) due cause ( e.g. , chemotherapy , diabetes , alcohol , toxin , heredity ) Other medical condition , opinion treat physician/allied health professional would make protocol unreasonably hazardous patient Any following : Pregnant woman Nursing woman Women childbearing potential unwilling employ adequate contraception Prior TAXOL and/or CBDCA chemotherapy treatment ( current treatment regimen ) Concurrent use agent use specifically prevent treat neuropathy , include limited following : Gabapentin Glutamine powder glutamine tablet Vitamin B6 E</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>